Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miricorilant Safety and Efficacy in Presumed NASH
NCT05117489Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Nov 2021
- Primary completion
- Jan 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of miricorilant in Nonalcoholic steatohepatitis (NASH) (11 cohorts), sponsored by Corcept Therapeutics. Primary endpoint: Relative change from Baseline in liver-fat content assessed by MRI-PDFF at 24 weeks. Started Nov 2021; status: completed.
02
Drugs
miricorilant
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05117489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117489.